Novel ALK fusion partners in lung cancer

Cancer Letters

Volumn 362, Issue 1, 2015, Pages 116-121

  Iyevleva, Aglaya G ^a,b   Raskin, Grigory A ^c   Tiurin, Vladislav I ^a   Sokolenko, Anna P ^a,b   Mitiushkina, Natalia V ^a   Aleksakhina, Svetlana N ^a   Garifullina, Aigul R ^a   Strelkova, Tatiana N ^a   Merkulov, Valery O ^a   Ivantsov, Alexandr O ^a   Kuligina, Ekatherina Sh ^a   Pozharisski, Kazimir M ^a,b   Togo, Alexandr V ^a   Imyanitov, Evgeny N ^a,b,d  

^a N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^b SAINT PETERSBURG STATE PEDIATRIC MEDICAL UNIVERSITY   (Russian Federation)

^c Russian Center for Research in Radiological and Surgical Technologies   (Russian Federation)

^d NORTH WESTERN STATE MEDICAL UNIVERSITY NAMED AFTER I I MECHNIKOV   (Russian Federation)

Author keywords

ALK; Fusion partner; Lung cancer; PCR; Rearrangement; Translocation

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; DYNACTIN; MICROTUBULE ASSOCIATED PROTEIN; ONCOPROTEIN; PROTEIN TYROSINE KINASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SQSTM1 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ADULT; AGED; ALK GENE; ARTICLE; CONTROLLED STUDY; DCTN1 GENE; EGFR GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE EXPRESSION; GENE FUSION; GENE MUTATION; GENE REARRANGEMENT; GENE TRANSLOCATION; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR TYPING; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SQSTM1 GENE; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PROCEDURES; YOUNG ADULT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; BASE SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION; GENE REARRANGEMENT; HUMANS; LUNG NEOPLASMS; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS, FUSION; POLYMERASE CHAIN REACTION; RECEPTOR PROTEIN-TYROSINE KINASES; TRANSLOCATION, GENETIC; YOUNG ADULT;

EID: 84931067455     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.03.028     Document Type: Article

References (34)

1. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med 2010, 363:1693-1703.
2. Iwama E., Okamoto I., Harada T., Takayama K., Nakanishi Y. Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer. Onco Targets Ther 2014, 7:375-385.
3. Kim H., Shim H.S., Kim L., Kim T.J., Kwon K.Y., Lee G.K., et al. Guideline recommendations for testing of ALK gene rearrangement in lung cancer: a proposal of the Korean Cardiopulmonary Pathology Study Group. Korean J. Pathol 2014, 48:1-9.
4. McKeage K. Alectinib: a review of its use in advanced ALK-rearranged non-small cell lung cancer. Drugs 2014, in press. 10.1007/s40265-014-0329-y.
5. Shaw A.T., Engelman J.A. Ceritinib in ALK-rearranged non-small-cell lung cancer. N. Engl. J. Med 2014, 370:2537-2539.
6. Thunnissen E., Bubendorf L., Dietel M., Elmberger G., Kerr K., Lopez-Rios F., et al. EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch 2012, 461:245-257.
7. Lindeman N.I., Cagle P.T., Beasley M.B., Chitale D.A., Dacic S., Giaccone G., et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J. Mol. Diagn 2013, 15:415-453.
8. Marchetti A., Ardizzoni A., Papotti M., Crinò L., Rossi G., Gridelli C., et al. Recommendations for the analysis of ALK gene rearrangements in non-small-cell lung cancer: a consensus of the Italian Association of Medical Oncology and the Italian Society of Pathology and Cytopathology. J. Thorac. Oncol 2013, 8:352-358.
9. Cooper W., Fox S., O'Toole S., Morey A., Frances G., Pavlakis N., et al. National Working Group Meeting on ALK diagnostics in lung cancer. Asia Pac. J. Clin. Oncol 2014, 10(Suppl. 2):11-17.
10. Shackelford R.E., Vora M., Mayhall K., Cotelingam J. ALK-rearrangements and testing methods in non-small cell lung cancer: a review. Genes Cancer 2014, 5:1-14.
11. Tembuyser L., Tack V., Zwaenepoel K., Pauwels P., Miller K., Bubendorf L., et al. The relevance of external quality assessment for molecular testing for ALK positive non-small cell lung cancer: results from two pilot rounds show room for optimization. PLoS ONE 2014, 9:e112159.
12. von Laffert M., Warth A., Penzel R., Schirmacher P., Jonigk D., Kreipe H., et al. Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): results of a multi-centre ALK-testing. Lung Cancer 2013, 81:200-206.
13. Cabillic F., Gros A., Dugay F., Begueret H., Mesturoux L., Chiforeanu D.C., et al. Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances. J. Thorac. Oncol 2014, 9:295-306.
14. Cutz J.C., Craddock K.J., Torlakovic E., Brandao G., Carter R.F., Bigras G., et al. Canadian anaplastic lymphoma kinase study: a model for multicenter standardization and optimization of ALK testing in lung cancer. J. Thorac. Oncol 2014, 9:1255-1263.
15. Mitiushkina N.V., Iyevleva A.G., Poltoratskiy A.N., Ivantsov A.O., Togo A.V., Polyakov I.S., et al. Detection of EGFR mutations and EML4-ALK rearrangements in lung adenocarcinomas using archived cytological slides. Cancer Cytopathol 2013, 121:370-376.
16. Wang R., Pan Y., Li C., Hu H., Zhang Y., Li H., et al. The use of quantitative real-time reverse transcriptase PCR for 5' and 3' portions of ALK transcripts to detect ALK rearrangements in lung cancers. Clin. Cancer Res 2012, 18:4725-4732.
17. Gruber K., Horn H., Kalla J., Fritz P., Rosenwald A., Kohlhäufl M., et al. Detection of rearrangements and transcriptional up-regulation of ALK in FFPE lung cancer specimens using a novel, sensitive, quantitative reverse transcription polymerase chain reaction assay. J. Thorac. Oncol 2014, 9:307-315.
18. Moiseyenko V.M., Procenko S.A., Levchenko E.V., Barchuk A.S., Moiseyenko F.V., Iyevleva A.G., et al. High efficacy of first-line gefitinib in non-Asian patients with EGFR-mutated lung adenocarcinoma. Onkologie 2010, 33:231-238.
19. Togashi Y., Soda M., Sakata S., Sugawara E., Hatano S., Asaka R., et al. KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS ONE 2012, 7:e31323.
20. Gridelli C., de Marinis F., Cappuzzo F., Di Maio M., Hirsch F.R., Mok T., et al. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology. Clin. Lung Cancer 2014, 15:173-181.
21. Murakami Y., Mitsudomi T., Yatabe Y. A screening method for the ALK fusion gene in NSCLC. Front. Oncol 2012, 2:24.
22. Schroer T.A. Dynactin. Annu. Rev. Cell Dev. Biol 2004, 20:759-779.
23. Kim H., Ling S.C., Rogers G.C., Kural C., Selvin P.R., Rogers S.L., et al. Microtubule binding by dynactin is required for microtubule organization but not cargo transport. J. Cell Biol 2007, 176:641-651.
24. Lazarus J.E., Moughamian A.J., Tokito M.K., Holzbaur E.L. Dynactin subunit p150(Glued) is a neuron-specific anti-catastrophe factor. PLoS Biol 2013, 11:e1001611.
25. Moughamian A.J., Osborn G.E., Lazarus J.E., Maday S., Holzbaur E.L. Ordered recruitment of dynactin to the microtubule plus-end is required for efficient initiation of retrograde axonal transport. J. Neurosci 2013, 33:13190-13203.
26. Farrer M.J., Hulihan M.M., Kachergus J.M., Dächsel J.C., Stoessl A.J., Grantier L.L., et al. DCTN1 mutations in perry syndrome. Nat. Genet 2009, 41:163-165.
27. Caroppo P., Le Ber I., Clot F., Rivaud-Péchoux S., Camuzat A., De Septenville A., et al. DCTN1 mutation analysis in families with progressive supranuclear palsy-like phenotypes. JAMA Neurol 2014, 71:208-215.
28. Murga-Zamalloa C., Lim M.S. ALK-driven tumors and targeted therapy: focus on crizotinib. Pharmgenomics Pers. Med 2014, 7:87-94.
29. Busam K.J., Kutzner H., Cerroni L., Wiesner T. Clinical and pathologic findings of Spitz nevi and atypical Spitz tumors with ALK fusions. Am. J. Surg. Pathol 2014, 38:925-933.
30. Komatsu M., Kageyama S., Ichimura Y. p62/SQSTM1/A170: physiology and pathology. Pharmacol. Res 2012, 66:457-462.
31. Laurin N., Brown J.P., Morissette J., Raymond V. Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am. J. Hum. Genet 2002, 70:1582-1588.
32. Takeuchi K., Soda M., Togashi Y., Ota Y., Sekiguchi Y., Hatano S., et al. Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma. Haematologica 2011, 96:464-467.
33. Vidal J., Clavé S., de Muga S., González I., Pijuan L., Gimeno J., et al. Assessment of ALK status by FISH on 1000 Spanish non-small cell lung cancer patients. J. Thorac. Oncol 2014, 9:1816-1820.
34. Wang J., Cai Y., Dong Y., Nong J., Zhou L., Liu G., et al. Clinical characteristics and outcomes of patients with primary lung adenocarcinoma harboring ALK rearrangements detected by FISH, IHC, and RT-PCR. PLoS ONE 2014, 9:e101551.